Simon Coulthard Appointed New CFO of Pangaea Data

Simon Coulthard is a Fellow of the Chartered Institute of Management Accountants with thirty years of accounting and financial leadership experience.

In addition, Professor Mark Musen, Dr. Rick Sax, and Mr. Ozgur Tuncer have been added to its Scientific Advisory Board.

Simon Coulthard joins Pangaea from Congenica, a cutting-edge digital health company spun out of the Wellcome Sanger Institute, where he was instrumental in their recent $50m Series C funding round.

Simon Coulthard has grown companies from early-stage to market leaders, and has experienced private equity-backed buy-outs, and has exited companies through secondary sales, doubling the enterprise value to £55m in 18 months. He will leverage the benefits of a decade of international experience in software development and the recent global growth in Congenica’s digital health platform to accelerate the expansion of Pangaea’s product offerings in key strategic markets within the US healthcare and pharmaceutical industry. Mr. Coulthard will be in charge of the financial reporting, planning, and analysis, accounting, business intelligence, and controls to ensure that governance and other financial foundations are in place to support the rapid expansion of Pangaea’s commercial operations on a global scale.

Professor Mark Musen is a professor of Biomedical Informatics and Director of the Stanford Centre for Biomedical Informatics Research at Stanford University. He chaired the Health Informatics and Modelling Topic Advisory Group for the World Health Organisation’s revision of the International Classification of Diseases (ICD) and is also the principal investigator of Center for Expanded Data Annotation and Retrieval (CEDAR). Professor Musen’s wealth of experience and knowledge will help Pangaea to scale its presence in the US and apply its novel AI through new collaborations in the US.

Dr. Rick Sax, previously a Senior Vice President at IQVIA and formerly a Clinical Vice-President at AstraZeneca and Mr. Ozgur Tuncer, Global Vice President, Financial Institutions at IQVIA and Investment Partner at Ascension Life Sciences Fund, have also joined Pangaea as senior advisors.

Dr. Sax has established himself as an expert on drug research and development, advising UK and US venture capitalists on the risk perspective of pharmaceutical investments and asset development strategies.

Mr. Tuncer advises senior decision-makers in the biopharmaceutical industry across Europe, the USA, and the Middle East, focusing on M&A, valuations, and portfolio management. Their addition to Pangaea’s SAB will help the company explore strategic opportunities with key stakeholders in the life sciences industry and further develop the current product offering to help scientists and clinicians transform currently manual processes so they can focus on their core aspects of scientific interpretation and clinical decision making.

These appointments firmly establish Pangaea as a leader within the Life Sciences sector and help shape the company’s future growth strategy. This includes the expansion of the application of Pangaea’s breakthrough AI, which helps pharmaceutical companies unlock hidden value from textual data for the benefit of finding more suitable patients at scale for drug discovery, clinical trials, and new product (drug) launches. The company has successfully extended the application of its AI for automatic generation of clinical study reports and similar documents based on tables of experimental data; and for faster discovery of adverse events, which is critical for pharmacovigilance.

Speaking on the appointment, Mr. Simon Coulthard, CFO of Pangaea Data commented “I am delighted to join the team at Pangaea. The work they have been doing using AI to extract vital information from doctors’ notes, discharge summaries, and other sources is revolutionizing how the pharmaceutical industry finds cohorts for drug trials, taking a process that usually takes several months down to a few weeks. The connections they have already established with key players in the pharmaceutical market clearly demonstrate their unique offering. I look forward to working with the leadership team to further scale the business and achieve increasing recurring revenues as their platform is used for multiple applications across an enterprise.”

Dr. Vibhor Gupta, Founder, and CEO of Pangaea Data stated “The additions of Mr. Simon Coulthard, Professor Mark Musen, Dr. Rick Sax, and Mr. Ozgur Tuncer to our team will have a significant impact on the growth of our company. Their combined industry experiences of more than 60 years and global networks are unparalleled. At a time when our novel AI is being embedded within the core life sciences infrastructure, their knowledge will be invaluable to help us scale and expand in new markets.”

Hot this week

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.